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Patients typically present with insidious onset of an asymptomatic, salmon-coloured, well-demarcated mass. Uncommonly, lymphoma may occur following treatment with immunosuppressive medications. 2 We present a case of conjunctival lymphoma that presented 4 years after treatment with cyclophosphamide. Although the association may be coincidental, our case emphasizes that physicians should be alert to the possibility of secondary malignancy occurring in the eye following systemic immunosuppression.
Case report
A 68-year-old man, with a history of sympathetic ophthalmia that occurred 6 years earlier, noticed a painless red mass in his right eye. Therapy for sympathetic ophthalmia included prednisone and a 6-month course of cyclophosphamide 50 mg/day. His past ocular history was otherwise notable for multiple intraocular surgeries in the right eye for cataract and open-angle glaucoma. On presentation, his visual acuity was 20/25 OU. Examination of the right conjunctiva revealed a salmon-coloured, vascularized mass from 1 o'clock to 3 o'clock ( Figure 1 ). Fundus examination revealed a sunset glow appearance and chorioretinal scars bilaterally.
Biopsy revealed a diffuse lymphocytic stromal infiltrate (Figure 1b) . Most lymphocytes were enlarged, with variable cytoplasm, irregular nuclei, and intranuclear inclusions (Dutcher bodies). Immunophenotyping revealed strong CD20 and kappa light chain positivity. The histopathological diagnosis was a low-grade B-cell lymphoma that was mostly consistent with marginal zone lymphoma. This type of lymphoma is often referred to as mucosa-associated lymphoid tissue lymphoma. Treatment involves evaluation for systemic disease. Localized conjunctival lymphoma may be treated with radiotherapy, although some cases may be cured by local excision.
Comment
Long-term studies of patients treated with cyclophosphamide showed an increased risk for malignancy, including lymphomas.
2-4 Hoffman et al 2 observed a 2.4-fold overall increase in the incidence of malignancies, and an 11-fold greater incidence of systemic lymphomas in the general population. The risk appears to be dose-dependent, particularly with cumulative doses 450 g, but is also reported with lower doses, and may develop for up to 10 years. 5 Our patient received a total of 9 g. Potential mechanisms of malignancy include induced chromosomal alterations, altered immune-mediated anti-tumour surveillance, and increased susceptibility to oncogenic agents.
3 Although the possibility remains that the association was spurious, our report of conjunctival lymphoma following treatment with systemic cyclophosphamide is the first report of such a secondary ocular malignancy, and illustrates that physicians should be alert to the possibility of secondary malignancy occurring in the eye following systemic immunosuppression.
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The authors declare no conflict of interest. Sir, Coats' disease associated with muscular dystrophy treated with ranibizumab
Coats' disease can be associated with muscular dystrophy. We present a case in which ranibizumab was used for Coats' disease associated with a muscular dystrophy.
Case report
An 18-year-old man came to our department because he had noted decreased vision in his left eye. The patient had no systemic complaints. The best-corrected visual acuity (VA) was 20/20 in his right eye (RE) and count fingers in his left eye (LE). The anterior segment was unremarkable. Fundus examination showed hard circinate exudates, telangiectatic vessels, microaneurysms, and venous dilatation only in the LE (Figures 1a and b) . The patient underwent fluorescein angiography (Figures 1c and d ) and optic coherence tomography (OCT) (Figure 2 ). Coats' disease was confirmed.
A complete blood count, liver and muscle enzymes and coagulation testing was performed. The patient showed a consistently elevated creatine phosphokinase on repeat testing of 3000 UI/ml. We referred the patient to a neurologist, who performed the diagnosis of facioscapulohumeral dystrophy (FSHD).
Peripheral argon laser photocoagulation and three ranibizumab injections were administered to the LE. The VA improved to 20/60 and has stayed stable with 1 year of follow-up (Figure 3 ).
Comment
Coats' disease is characterized by vascular abnormalities, commonly telangiectatic vessels and retinal exudation. Normally only one eye is involved and predominantly men are affected before 20 years of age.
1,2 Usually, it is not necessary to do a systemic study with typical signs of Coats' disease but there are some cases of muscular and facioscapulohumeral dystrophies associated with Coats' 
